Managing oral anticoagulation therapy: improving clinical outcomes. A review

Journal of Clinical Pharmacy and Therapeutics
F RyanS O'Shea

Abstract

Many physicians are reluctant to prescribe oral anticoagulation therapy (OAT) because of the fear of haemorrhagic complications. Changes in patient health, lifestyle or diet and other drugs can alter the effectiveness of oral anticoagulants. These potential interferences, added to the fact that each individual has a different reaction to these drugs, requires that therapy is monitored regularly. This article aims to review those strategies which help to achieve optimal anticoagulation control and improve the outcomes of OAT. Relevant articles were identified through a search of MEDLINE and included publications reporting on intensity of anticoagulation, the initiation of therapy and the role of pharmacogenetics, the transition from primary to secondary care, management by specialized clinics using decision support software and home-testing. Implementation of these strategies would increase the use of oral anticoagulants by physicians and offers the potential to improve patient safety and reduce adverse events.

References

Apr 28, 1984·British Medical Journal·A FennertyP A Routledge
Jul 6, 1995·The New England Journal of Medicine·S C CannegieterE Briët
Jan 1, 1996·Journal of Clinical Pathology·P E Rose
Jan 15, 1997·Annals of Internal Medicine·L HarrisonJ Hirsh
Dec 1, 1996·Journal of General Internal Medicine·R J BeythC S Landefeld
Jul 1, 1997·The American Journal of Medicine·J H ArnstenD E Singer
Sep 3, 1998·International Journal of Medical Informatics·G ChatellierP Degoulet
Sep 12, 1998·British Journal of Haematology·D A FitzmauriceR McManus
Jan 19, 1999·Archives of Internal Medicine·M A CrowtherJ Hirsh
Jan 23, 1999·JAMA : the Journal of the American Medical Association·J E Ansell
May 18, 1999·Seminars in Thrombosis and Hemostasis·W KulinnaJ Harenberg
Jun 12, 1999·Journal of Thrombosis and Thrombolysis·S Erban
Jan 27, 2000·Archives of Internal Medicine·E P LeshoD Asquith
Feb 26, 2000·Age and Ageing·G Y Lip, F L Li-Saw-Hee
Apr 15, 2000·Journal of Thrombosis and Thrombolysis·D HorstkotteM Wiemer
Dec 31, 2002·The Annals of Pharmacotherapy·Elaine Othilia Y L TangThomas Y K Chan
Feb 1, 2003·Annals of Internal Medicine·Alan J ForsterDavid W Bates
Dec 24, 2003·Thrombosis and Haemostasis·Brian F GageHoward L McLeod
Oct 13, 2004·Archives of Internal Medicine·Nadya KaganskyShmuel Levy
Jan 5, 2005·Annals of Internal Medicine·Bárbara Menéndez-JándulaJordi Fontcuberta
Oct 4, 2005·British Journal of Haematology·D A FitzmauriceUNKNOWN British Society of Haematology Taskforce for Haemostasis and Thrombosis
Oct 12, 2005·BMJ : British Medical Journal·D A FitzmauriceF D R Hobbs
Jan 18, 2006·British Journal of Haematology·T P BaglinUNKNOWN British Committee for Standards in Haematology
Jun 21, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Dean A RegierCarlo A Marra

❮ Previous
Next ❯

Citations

Mar 29, 2011·International Journal of Clinical Pharmacy·Laura SahmHelen L Richards
Oct 7, 2014·The American Journal of the Medical Sciences·Souvik Sen, Katherine Willett Dahlberg
May 17, 2011·Thrombosis Research·Hayan Moualla, David Garcia
Nov 16, 2013·Drug Metabolism and Drug Interactions·Sarah Fetterman Hale, Timothy S Lesar
May 17, 2017·International Journal of Clinical Pharmacy·Nahid Osman AhmedTariq Muhammed Hashim El-Hadiyah
Apr 23, 2019·International Journal of Clinical Pharmacy·Elena M MifsudAnthony Serracino-Inglott

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.